County Budget Concerns Several Counties that are in the process of implementing the CARE Act have raised concerns to the Governor and Budget Chairs regarding the failure to include funding for counsel for county behavioral health agencies who are responsible
This past year has been a truly inspiring one. I learned tremendously from the other Board Members, the Government Affairs Committee members, and the intense and thought-provoking discussions had at the respective meetings. It has been eye-opening to learn about
The work continues. CSAP is working in tandem with the American Psychiatric Association (APA) to address prescribing issues on the federal level. Congress put out a request for information on the national drug shortage and APA wants to better understand how far reaching
Register for the 2023 Annual Meeting Virtual Summer Courses APA is excited to announce the start of the 2023 APA Annual Meeting Virtual Summer Courses! These courses are designed to provide you with an immersive learning experience led by leading experts covering
The Assembly Select Committee on California’s Mental Health Crisis held its third hearing this week: Where do we go from here? You may view the agenda and SYASL staff notes from the hearing below. AgendaSYASL Staff Notes
May Equity Working Group Meeting Today, the California Health & Human Services Agency (CalHHS) held its Equity Working Group. You may view SYASL staff notes from the meeting here. Upcoming Webinar The California Health & Human Services Agency (CalHHS), in partnership with its departments,
Upcoming CARE Act Training and Technical Assistance: Eligibility in Practice on June 14 Health Management Associates (HMA) will provide a training session on Wednesday, June 14, from 9 a.m. to 10 a.m., to cover CARE Act eligibility criteria, including a review
Effective February 2023, the California Department of Public Health (CDPH) added the following antipsychotic injectables to the ADAP formulary: Aripiprazole (Abilify Maintena®), Aripiprazole (Aristada®), Olanzapine (Zyprexa Relprevv™), Paliperidone (Invega Sustenna®), Risperidone (Risperdal Consta®). The addition of these medications provides options
